BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 10921025)

  • 1. [Inhibition of apoptosis by bcr-abl fusion gene in K562 cells].
    Wang C; Sun B; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 1998 Sep; 20(5):340-1. PubMed ID: 10921025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells.
    Zhang KZ; Xu JH; Huang XW; Wu LX; Su Y; Chen YZ
    Acta Pharmacol Sin; 2007 Jan; 28(1):105-10. PubMed ID: 17184589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Construction of retrovirus vector of bcr/abl mRNA cleaving ribozyme gene and its effects on K562 cells].
    Wu Y; Chen Y; Hu J
    Zhonghua Xue Ye Xue Za Zhi; 1998 Dec; 19(12):623-6. PubMed ID: 11263328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptotic effect of As2S2 on K562 cells and its mechanism.
    Li JE; Wu WL; Wang ZY; Sun GL
    Acta Pharmacol Sin; 2002 Nov; 23(11):991-6. PubMed ID: 12421474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference.
    Bártová E; Harnicarová A; Pacherník J; Kozubek S
    Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on the in vitro cleavage abilities of ribozymes specific to different sites of bcr-abl fusion gene and their induction of apoptosis in K562 cells].
    Feng Q; Sun B; Zhao Y
    Zhonghua Yi Xue Za Zhi; 2000 Feb; 80(2):127-30. PubMed ID: 11798747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of multi-unit ribozymes on the growth inhibition and apoptosis induction of CML K562 cells].
    Feng Q; Sun B; Sun K; Shang Z; Wang S; Wang W; Zhao Y; Yan Z; Han W; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):435-9. PubMed ID: 12485492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of anti-ABL tyrosine kinase intrabody on the growth of K562 cells in nude mice].
    Xu D; Song JM; Hu Y; Guo H; Cao DJ; Wang P; Liu H; Zhao CH
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Feb; 24(1):11-4. PubMed ID: 12905832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
    Pytel D; Wysocki T; Majsterek I
    Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
    Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
    Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
    Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
    Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
    Lothstein L; Savranskaya L; Sweatman TW
    Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
    Sengupta A; Banerjee D; Chandra S; Banerjee S
    J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibitory effect of RNA interference on chronic myeloid leukemia bcr/abl oncogene expression].
    Ma XX; Wang C; Wei J; Qin YW; Yan SK; Gao YR; Cai Q
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):359-62. PubMed ID: 16185484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
    Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
    Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir.
    Rivas C; Miller AR; Collado M; Lam EW; Apperley JF; Melo JV
    Mol Ther; 2001 May; 3(5 Pt 1):642-52. PubMed ID: 11356068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.